HIV Incidence and Participation Retention in Pune, India
NCT ID: NCT00028119
Last Updated: 2022-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1070 participants
OBSERVATIONAL
2002-08-31
2005-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Phase III studies of HIV prevention require the participation of a large number of people at high risk for HIV infection. It is also important that these participants continue and follow through with the study through the extended period of follow-up. A measurement of HIV incidence and retention rate among high-risk women and HIV-discordant couples is necessary for upcoming HPTN trials. Taken together with the need for estimates of HIV incidence and the need for data to ensure high retention rates, this protocol is important for the HPTN generally and for HPTU in Pune in particular.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation and Monitoring of Patients With HIV Infectionn
NCT00557570
Clinical Epidemiology Cohort Study for Patient Living With HIV
NCT04061889
Acute HIV Infection Observational Study
NCT00296660
Screening Protocol for HIV Vaccine Studies
NCT00031304
The Detection of Drug-Resistant HIV-1 in Taiwan
NCT00690001
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Potential study participants will undergo eligibility screening, including administration of a questionnaire, physical examination, and HIV antibody testing. Once participants are enrolled in the study, the requirements will include follow-up every 3 months for 17.5 months, phlebotomy, physical exams, and questionnaires. At every follow-up visit, a short questionnaire will be administered to all participants to assess their continued understanding about the nature, duration, benefits and risks of being in the study and to assure their voluntary participation in the study. Participants seen in follow-up also will have a physical examination, be evaluated and treated for any STDs, receive additional counseling, and be offered retesting for HIV infection. In addition, participants also will be invited to participate in additional assessment issues addressing retention using a series of focus groups, key informant interviews, and individual qualitative and quantitative assessments. Participants in this protocol may also be eligible to enroll into 1 of 2 proposed ancillary laboratory substudies (HPTN 034A and 034B).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
HIV-uninfected non-sex worker women
No interventions assigned to this group
Cohort 2
HIV-discordant heterosexual couples attending STD clinics
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years old.
* Able and willing to provide written informed consent for HIV testing and to take part in this study.
* Willing to receive their HIV test results.
* HIV-negative.
* Available for at least 17.5 months of study follow-up.
HIV-infected partners (index partner) in the HIV-discordant couples may be eligible if they are:
* At least 18 years old.
* Able and willing to provide written consent for HIV testing and to take part in this study.
* Willing to receive their HIV test results.
* HIV-positive.
* Available for at least 17.5 months of study follow-up.
* Presently in a sexual relationship with the same partner for at least 3 months.
* Intending to remain with this partner for the duration of the study.
* Willing to identify his/her sexual partner and disclose his/her HIV status to partner.
* Willing to attempt to recruit their partner.
Partners of HIV-infected index partners in the HIV-discordant couples may be eligible if they are:
* At least 18 years old.
* Able and willing to provide written consent for HIV testing.
* Willing to receive their HIV test results.
* HIV-negative.
HIV-discordant couples may be eligible if they first meet the criteria in 2 and 3 above and also if:
* Each partner agrees to participate in the study together.
* Each partner is able and willing to provide written informed consent to take part in the study.
* The partners have been in a sexual relationship for at least the prior 3 months.
* Each partner is available for at least 17.5 months of study follow-up.
* Each couple has stated intention to continue their relationship for at least 17.5 months.
* Each partner is willing and able to attend each scheduled follow-up study visit.
Exclusion Criteria
* Are HIV-uninfected women who report a history of prior commercial sex work. However, HIV-infected female commercial sex workers can be enrolled in the HIV-discordant partners study with their HIV-uninfected male sexual partner.
* Have mental problems that would interfere with study participation.
* Have any other condition that, in the opinion of the investigator, would interfere with the study.
* Are an HIV-discordant couple that reports a history of domestic violence.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
HIV Prevention Trials Network
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Bollinger
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins University
Sanjay Mehendale
Role: PRINCIPAL_INVESTIGATOR
NARI Pune CRS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National AIDS Research Institute
Pune, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HPTN 034B substudy
Identifier Type: -
Identifier Source: secondary_id
HPTN 034A substudy
Identifier Type: -
Identifier Source: secondary_id
HPTN 034
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.